PPARGC1A and metabolic dysfunction-associated steatotic liver disease: In the validation set, consistent with the training set, ERN1 and SLC11A1 expression remained significantly lower in the NAFLD group compared with controls, whereas no significant differences were observed for PPARGC1A, MYC, or TLR7 (Supplementary Figure S1D).